Nathan M. Jameson

1.0k total citations
7 papers, 172 citations indexed

About

Nathan M. Jameson is a scholar working on Molecular Biology, Cancer Research and Organic Chemistry. According to data from OpenAlex, Nathan M. Jameson has authored 7 papers receiving a total of 172 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 2 papers in Cancer Research and 1 paper in Organic Chemistry. Recurrent topics in Nathan M. Jameson's work include CRISPR and Genetic Engineering (2 papers), Beetle Biology and Toxicology Studies (1 paper) and RNA modifications and cancer (1 paper). Nathan M. Jameson is often cited by papers focused on CRISPR and Genetic Engineering (2 papers), Beetle Biology and Toxicology Studies (1 paper) and RNA modifications and cancer (1 paper). Nathan M. Jameson collaborates with scholars based in United States, Switzerland and Norway. Nathan M. Jameson's co-authors include Jorge A. Benítez, Frank B. Furnari, Jianhui Ma, Jeffrey A. Winkles, Matteo D’Antonio, Kelly A. Frazer, Webster K. Cavenee, Timothy G. Whitsett, Hrvoje Miletić and Antonia Boyer and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Nathan M. Jameson

7 papers receiving 172 citations

Peers

Nathan M. Jameson

MB

CR

ONCOL

GENET

IMMUN

Cinzia Cantù Italy

Ana Jimenez‐Pascual United Kingdom

Kiranmai Alapati United States

María del Mar Inda Spain

Chithra Subramani United Kingdom

Mariaelena Pistoni Italy

Lisa M. DeCamp United States

Danielle Bozek Canada

Aniello Federico Germany

Anja Wieland Germany

Cinzia Cantù Italy

Nathan M. Jameson

136 ×1.1

MB

96 ×1.3

CR

69 ×1.5

ONCOL

19 ×0.6

GENET

17 ×0.7

IMMUN

Citations per year, relative to Nathan M. Jameson Nathan M. Jameson (= 1×) peers Cinzia Cantù

Countries citing papers authored by Nathan M. Jameson

Since Specialization

Citations

This map shows the geographic impact of Nathan M. Jameson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan M. Jameson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan M. Jameson more than expected).

Fields of papers citing papers by Nathan M. Jameson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan M. Jameson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan M. Jameson. The network helps show where Nathan M. Jameson may publish in the future.

Co-authorship network of co-authors of Nathan M. Jameson

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan M. Jameson. A scholar is included among the top collaborators of Nathan M. Jameson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan M. Jameson. Nathan M. Jameson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Jameson, Nathan M., Catherine Lee, Xiao Guo, et al.. (2025). The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRAS G12C Inhibitors in Preclinical Models. Cancer Research Communications. 5(2). 240–252. 3 indexed citations

2.

Avutu, Viswatej, J. Andrew Livingston, Noah Federman, et al.. (2024). Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma.. Journal of Clinical Oncology. 42(16_suppl). 11525–11525. 2 indexed citations

3.

Liu, Wen, Heekyung Chung, Hooman Izadi, et al.. (2023). Abstract 2153: Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1. Cancer Research. 83(7_Supplement). 2153–2153. 3 indexed citations

4.

Jameson, Nathan M., Jianhui Ma, Jorge A. Benítez, et al.. (2019). Intron 1–Mediated Regulation of EGFR Expression in EGFR-Dependent Malignancies Is Mediated by AP-1 and BET Proteins. Molecular Cancer Research. 17(11). 2208–2220. 9 indexed citations

5.

Benítez, Jorge A., Jianhui Ma, Matteo D’Antonio, et al.. (2017). PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications. 8(1). 15223–15223. 96 indexed citations

6.

Dhruv, Harshil, Timothy G. Whitsett, Nathan M. Jameson, et al.. (2013). Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation. Carcinogenesis. 35(1). 218–226. 14 indexed citations

7.

Whitsett, Timothy G., Emily H. Cheng, Landon J. Inge, et al.. (2012). Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion. American Journal Of Pathology. 181(1). 111–120. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact